Wandering Ozurdex(®) implant

PURPOSE: To report the behavior of intravitreal Ozurdex(®) implant in eyes with post-lensectomy–vitrectomy (PLV) aphakia. METHODS: Retrospective chart review of three eyes with PLV aphakia (three patients with uveitis) who received intravitreal injection of Ozurdex(®) for cystoid macular edema (one eye), persistent inflammation (one eye), and ocular hypotony (one eye). Final outcome was assessed in terms of effectiveness, stability, and tolerance of the implant. RESULTS: Following the implant, an initial improvement was seen in all the three eyes. However, the implant migrated into the anterior chamber (AC) at 1 week in two eyes and at 5 weeks in one eye, and wandered between the AC and vitreous cavity with changing postures of the patient. Two eyes developed corneal edema, of which one eye underwent implant removal from the AC. CONCLUSION: Ozurdex(®) implant should be contraindicated in eyes with PLV aphakia to avoid its deleterious effect on the corneal endothelium.